Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

Sipuleucel‐T is an investigational active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. The safety and efficacy of sipuleucel‐T was evaluated in 2 identically designed, randomized, double‐blind, placebo‐controlled trials (D9901 and D9902A) conducted in men with advanced prostate cancer.

[1]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[2]  N. James,et al.  3LB ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases , 2007 .

[3]  P. Schellhammer,et al.  Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC) , 2007 .

[4]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Kantoff,et al.  Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Small,et al.  Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. , 2005, Clinical prostate cancer.

[7]  J. Moul,et al.  Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer* , 2005, Current opinion in urology.

[8]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[9]  S. Vuk-Pavlović,et al.  Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial , 2004, The Prostate.

[10]  David J. Lee.  Clinical trials of atrasentan in hormone-refractory prostate cancer. , 2003, Clinical prostate cancer.

[11]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[12]  N. Goldstein.  Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. , 2002, American journal of clinical pathology.

[13]  M. Peshwa,et al.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Buckner,et al.  Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  F. Meyers,et al.  Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Schellhammer,et al.  Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. , 1997, The Journal of urology.

[18]  E. Small,et al.  Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Scher,et al.  Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. , 1996, Urology.

[20]  E. Small,et al.  The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer , 1995, Cancer.

[21]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Heyderman,et al.  A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. , 1989, British Journal of Cancer.

[23]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[24]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.